Related Experiment Video
Updated: Aug 13, 2026
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes
Setareh Shams'ili1, Janet de Beukelaar, Jan Willem Gratama
1Dept. of Neurology, Erasmus MC, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
Abstract:
Anti-CD20 monoclonal antibody (rituximab) is effectively used in the treatment of B-cell lymphomas. Recent reports in the literature suggest that antibody associated autoimmune disorders may respond to rituximab. We therefore treated nine patients with anti-Hu or anti-Yo associated paraneoplastic neurological syndromes (PNS) with a maximum of four monthly IV infusions of rituximab (375mg/m(2)). In this uncontrolled, unblinded trial of rituximab, three patients improved > or =1 point on the Rankin Scale (RS). One patient with limbic encephalitis improved dramatically (RS from 5 to 1). Further studies of rituximab in autoantibody associated PNS are warranted.
